Market Overview

Jazz Pharma Upgraded On Bullish Pipeline Forecast, Earnings Growth Visibility, M&A Potential

Jazz Pharma Upgraded On Bullish Pipeline Forecast, Earnings Growth Visibility, M&A Potential
Related JAZZ
88 Biggest Movers From Yesterday
The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Morgan Stanley named three reasons for its positive opinion on Irish pharma company Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) in a Monday report. 

The Analyst

Analyst David Risinger upgraded shares of Jazz Pharma from Equal-weight from Overweight and increased the price target from $167 to $183.

The Thesis 

Comments from Jazz Pharma on March 13 implied conviction in strong 2018 growth and M&A optionality, Risinger said.

A potential competitive threat from Avadel Pharmaceuticals PLC (ADR) (NASDAQ: AVDL) to Jazz' No.1 drug Xyrem appears to be significantly delayed, the analyst said. 

Jazz's two new drug candidates — JZP-258, a version of Xyreum with 90 percent lower sodium Xyreum, and solriamfetol for wakefulness — are generating increasing enthusiasm, the analyst said. The analyst's increased confidence in JZP-258 succeeding in a Phase 3 trial in early 2019 stems from the likelihood that the company may choose not to file JZP-507, which is a 50-percent lower sodium Xyrem, in mid-2018.

"Additionally, we expect FDA to approve novel wakefulness drug solriamfetol, which appears to have a best-in-class profile, in December 2018," Risinger said. 

Morgan Stanley is confident that Jazz Pharma will be able to extend the durability of its Xyrem franchise and add future growth drivers. The markets will come around to this view over time, Risinger said. 

Jazz, which traded in the $130-$155 range for the past eight months, is likely to break above the range on strong earnings growth visibility; the potential for multiple expansion amid investor confidence in the extension of the Xyrem franchise durability; and potential M&A optionality, according to Morgan Stanley. 

The Price Action

Jazz Pharma shares are up over 14 percent over the past year.

The stock was up 3.1 percent after the open Monday at $158.86. 

Related Links:

The Week Ahead In Biotech: Earnings, PDUFA Dates And More

UBS Likes The Tune Of Jazz Pharma's Settlement With Hikma

Latest Ratings for JAZZ

Nov 2018B. Riley FBRMaintainsBuyBuy
Aug 2018BMO CapitalMaintainsOutperformOutperform
Aug 2018Stifel NicolausMaintainsBuyBuy

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga


Related Articles (JAZZ + AVDL)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Fed Week Starts With A Hike Widely Expected, But Also Amid Hopes For More Clarity

KeyBanc: The Tesla Model 3 Is Fast And Elegant, But Maybe Too Simple